Sugita R, Komatsu N, Deguchi K, Okano K, Naito M, Yoshida Y, Watanabe H, Senba T, Harada S, Fukamoto K, Fujimaki Y
Sugita Otorhinolaryngologic Clinic.
Jpn J Antibiot. 1999 Oct;52(10):613-27.
We carried out clinical and bacteriological studies on clavulanic acid/amoxicillin and amoxicillin in pediatric sinusitis at 11 general practice settings. The results are summarized as follows. 1. The major isolated organisms from content of middle meatus were Streptococcus pneumoniae 32.2%, Haemophilus influenzae 32.0% and Moraxella subgenus Branhamella catarrhalis 25.1%. Similar results were observed for the major isolates from nasopharynx. 2. 62.1% of S. pneumoniae isolated were drug resistant S. pneumoniae (PISP, PRSP) and they were increasing year by year. 3. Drug resistant S. pneumoniae was isolated from 38.6% of all cases. 4. Regarding MIC90, CVA/AMPC showed superior antimicrobial activity against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella subgenus Branhamella catarrhalis. 5. The clinical efficacy, bacteriological efficacy and utility of CVA/AMPC-treated group were 78%, 58% and 72.8%, respectively, and they were significantly superior to AMPC-treated group. 6. Adverse reactions were observed in 11.2% of CVA/AMPC group, involving diarrhea and stool loose and there was no statistical deference from those of AMPC group.
我们在11个全科医疗机构对克拉维酸/阿莫西林和阿莫西林治疗小儿鼻窦炎进行了临床和细菌学研究。结果总结如下:1. 从中鼻道内容物中分离出的主要微生物为肺炎链球菌32.2%、流感嗜血杆菌32.0%和卡他莫拉菌(莫拉克斯氏菌属布兰汉菌亚属)25.1%。从鼻咽部分离出的主要菌株也观察到类似结果。2. 分离出的肺炎链球菌中有62.1%为耐药肺炎链球菌(PISP、PRSP),且逐年增加。3. 在所有病例中,38.6%分离出耐药肺炎链球菌。4. 关于MIC90,CVA/AMPC对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌(莫拉克斯氏菌属布兰汉菌亚属)显示出更强的抗菌活性。5. CVA/AMPC治疗组的临床疗效、细菌学疗效和效用分别为78%、58%和72.8%,均显著优于阿莫西林治疗组。6. CVA/AMPC组有11.2%出现不良反应,包括腹泻和大便稀溏,与阿莫西林组相比无统计学差异。